AUG 12, 2026 · PHASE 1 TRIAL
A Study to Evaluate ALN-6222 in Participants With Obesity
ClinicalTrials.gov
First-in-human Phase 1 trial with safety and tolerability as primary outcomes; no efficacy results are posted in this registry record.
Reported
Planned sample size88
Study phasePhase 1
Primary outcome measureFrequency of Adverse Events, Up to 12 months